Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2446 to 2460 of 7681 results

  1. Enfortumab vedotin with pembrolizumab for first-line treatment of unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy [ID6332]

    In development [GID-TA11233] Expected publication date: 04 June 2025

    Technology appraisal guidance
    In development

  2. Baloxavir marboxil for Influenza

    Awaiting development [GID-TA11646] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Evinacumab for treating homozygous familial hypercholesterolemia in children aged 5 to 11 TS ID 11806

      Status ...

    Technology appraisal guidance
    Topic selection

  4. Topical antimicrobial dressings for infected leg ulcers in people aged 16 and over: Late stage assessment

    In development [GID-HTE10041] Expected publication date: 22 May 2025

    Health technology evaluations
    In development

  5. Inhaled treprostinil for treating pulmonary hypertension caused by interstitial lung disease ID6459

    In development [GID-TA11572] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153]

    In development [GID-TA11090] Expected publication date: 18 June 2025

    Technology appraisal guidance
    In development

  7. Depemokimab for treating severe eosinophilic asthma in people 12 years and over ID6447

    Awaiting development [GID-TA11553] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Bimekizumab for treating moderate to severe hidradenitis suppurativa [ID6134]

    In development [GID-TA11045] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Compression products for treating venous leg ulcers: late stage assessment

    In development [GID-HTE10048] Expected publication date: 27 August 2025

    Health technology evaluations
    In development

  10. Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]

    Awaiting development [GID-TA10700] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Pneumonia: diagnosis and management (update)

    In development [GID-NG10357] Expected publication date: TBC

    NICE guideline
    In development

  12. Vosoritide for treating achondroplasia in people 4 months and over ID6488

    Awaiting development [GID-TA11528] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. One-piece closed bags for adults with a colostomy: Late Stage Assessment

    In development [GID-HTE10045] Expected publication date: TBC

    Health technology evaluations
    In development

  14. Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]

    Awaiting development [GID-TA10911] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Ovarian cancer QS update

    In development [GID-QS10182] Expected publication date: 05 February 2025

    Quality standard
    In development